Last reviewed · How we verify
Placebo - 0.9% w/v sodium chloride solution — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo - 0.9% w/v sodium chloride solution (Placebo - 0.9% w/v sodium chloride solution) — Merck Sharp & Dohme LLC. 0.9% sodium chloride solution is an isotonic saline that serves as a physiologically inert vehicle for drug delivery or as a control comparator in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo - 0.9% w/v sodium chloride solution TARGET | Placebo - 0.9% w/v sodium chloride solution | Merck Sharp & Dohme LLC | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo - 0.9% w/v sodium chloride solution CI watch — RSS
- Placebo - 0.9% w/v sodium chloride solution CI watch — Atom
- Placebo - 0.9% w/v sodium chloride solution CI watch — JSON
- Placebo - 0.9% w/v sodium chloride solution alone — RSS
Cite this brief
Drug Landscape (2026). Placebo - 0.9% w/v sodium chloride solution — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-0-9-w-v-sodium-chloride-solution. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab